Abstracts tagged "Mortality"

Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 0450 • ACR Convergence 2022
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Enrico Brunetta¹, Giacomo Ramponi², marco folci², Maria De Santis³, Giacomo Maria Guidelli¹, Angela Ceribelli⁴, Nicoletta Luciano¹, Marta Caprioli⁵, Arianna Sonaglia¹ and Carlo Selmi⁶, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Internal Medicine, Rozzano, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy
Background/Purpose: Serum antineutrophil cytoplasmic antibodies (ANCA) are significantly associated with the development of ANCA-associated vasculitides (AAV) but may also be detected in patients with other…
Abstract Number: 1444 • ACR Convergence 2022
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
YENFU CHEN and Yao-Fan Fang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Patients with systemic lupus erythematosus (SLE) had a higher risk of pericarditis, which could be life-threating, but there has been no research focusing on…
Abstract Number: 2085 • ACR Convergence 2022
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
Abstract Number: 0462 • ACR Convergence 2022
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
Mohanad Elfishawi¹, Mahmut Kaymakci², Sara Achenbach³, Cynthia Crowson⁴, Tanaz Kermani⁵, Cornelia Weyand⁴, Matthew J. Koster¹ and Kenneth J. Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
Abstract Number: 1453 • ACR Convergence 2022
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
Liza Rajasekhar¹, Vineetha Shobha², Meenakshi Ponnana³, Chengappa Kavadichanda⁴, Ashish J Mathew⁵, Saumya Ranjan Tripathy⁶, Manish Rathi⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Avinash Jain¹⁰ and Amita Aggarwal¹¹, ¹Nizam's Institute of Medical Sciences, Madhapur, India, ²St. John’s Medical College Hospital, Bangalore, India, ³Nizam's Institute of Medical Sciences, Hyderabad, India, ⁴JIPMER, Pondicherry, Puducherry, India, ⁵Rigshospitalet, Copenhagen, Denmark, ⁶SCB medical college, Cuttack, India, ⁷PGIMER Chandigarh, Chandigarh, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, India, ¹⁰SMS Medical College, Lucknow, India, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Muscle inflammation in systemic lupus erythematosus (SLE) usually presents as generalised myalgia in the presence of active disease elsewhere and responds well to treatment.…
Abstract Number: 2106 • ACR Convergence 2022
Disparities of African American Mortality Trends in South Carolina Lupus Cohort
Sean Carter¹, Dulaney Wilson¹, Samantha Minkin², David Dillon³, Baxter Murray¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Vanderbilt University Medical Center, Nashville, TN, ³Rheumatology Associates of South Florida, Delray Beach, FL
Background/Purpose: SLE is a chronic autoimmune disorder associated with increased mortality compared to the general population; treatment for SLE has improved and survival rates have…
Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Jacob Sode¹, Jens Rathmann¹, Anna Wilding², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel¹, Chengappa Kavadichanda³, Ashish J Mathew⁴, Ranjan Gupta⁵, Manish Rathi⁶, Parasar Ghosh⁷, Saumya Ranjan Tripathy⁸, Avinash Jain⁹ and Amita Aggarwal¹⁰, ¹St. John’s Medical College Hospital, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵All India Institute of Medical Sciences, New Delhi, India, ⁶PGIMER Chandigarh, Chandigarh, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Gregory McDermott¹, Keigo Hayashi², Kazuki Yoshida¹, Matthew Moll¹, Michael Cho¹, Tracy Doyle¹, Paul Dellaripa¹, Rachel Putman¹, Raul San Jose Estepar¹, George Washko¹, Elizabeth Regan³, Hiroto Hatabu¹, Gary M Hunninghake¹, Edwin Silverman¹ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Jewish Health, Denver, CO, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Anna Broder¹, Wenzhu B. Mowrey², Kazuki Yoshida³ and Karen Costenbader³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…
Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose felix Restrepo Suarez¹, Inmaculada Del Rincon¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science center at San Antonio, San Antonio, TX, ²University of Texas Health Sciences Center San Antonio, San antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].